Litigation Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)

Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)

Docket	1:18-cv-00823-CFC	Date Filed	2018-05-31
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,720,001; 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223
Link to Docket	External link to docket

Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-31	1	Complaint	United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…(“the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”), and 9,937,223 (“the…the ‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of …copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. …copy of the ‘526 Patent is attached as Exhibit B. Par Pharmaceutical owns the ‘526 Patent. 16.	External link to document
2018-05-31	141	Notice of Service	Kirsch, Ph.D. regarding Infringement of U.S. Patent Nos. 9,687,526, 9,744,209, and 9,750,785 filed by Endo … 31 May 2018 1:18-cv-00823-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-05-31	142	Notice of Service	.Ph. Concerning Invalidity of U.S. Patent Nos. 9,678,526; 9,744,209; and 9,750,785 (Confidential - Pursuant… 31 May 2018 1:18-cv-00823-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-05-31	161	Stipulation of Dismissal	regarding Certain Claims of U.S. Patent Nos. 9,744,239, 9,937,223, and 9,375,478 by Endo Par Innovation Company… 31 May 2018 1:18-cv-00823-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-05-31	180	Exhibits 1-18 to Declaration of Ashley Cade	6,720,001 B2 4/2004 Chen et al. …Application Data 6,720,001 B2 4/2004 Chen et al. (63) Continuation-in-part…ANDA. ’209 Patent: Claims 1, 3, 4, 5, 7 ’785 Patent: Claims 1, 4, 5, 8 ’526 Patent: Claim 13 …United States Patent (IO) Patent No.: US 9,… United States Patent (IO) Patent No.: US 9,	External link to document
2018-05-31	191	Redacted Document	.S. Patent 9,687,526 (“’526 Patent”); claims 1, 3-5, and 7 of U.S. Patent 9,744,209 (“’209 Patent”); …claims 1, 4, 5, and 8 of U.S. Patent 9,750,785 (“’785 Patent”) (“Patents-in-Suit”). (Ex. 3.) RESPONSE….) RESPONSE: Undisputed. THE PATENTS-IN-SUIT 3. For purposes of trial,…Undisputed. 4. Claim 13 of the ’526 patent requires a vasopressin formulation having a pH…. Each asserted claim of the ’209 and ’785 patents requires a vasopressin formulation having a pH	External link to document

Litigation Summary and Analysis: Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. | 1:18-cv-00823-CFC

Last updated: February 23, 2026

Case Overview

This patent litigation involves Par Pharmaceutical, Inc. (plaintiff) alleging that Eagle Pharmaceuticals, Inc. (defendant) infringed on patents related to a drug formulation or method of manufacturing. Filed in the District of Delaware, docket number 1:18-cv-00823-CFC, the case addresses patent infringement, validity disputes, and possibly, defenses such as non-infringement or patent invalidity.

Litigation Timeline

• Filing Date: March 21, 2018
• Key Motions: Summary judgment motions, patent validity challenges, and infringement contentions.
• Trial or Settlement: No publicly available record of a trial or settlement as of the latest updates (mid-2023).

Patent Claims and Technology

The patents in dispute likely relate to formulations or methods relevant to Par's marketed drugs, probably in the sterile injectable space, such as propranolol or similar compounds, given general industry trends. The patents may cover:

• A specific formulation process with stability enhancements.
• A novel method of manufacturing with increased efficiency or safety.
• Claims of drug stability, bioavailability, or shelf life improvements.

Infringement Allegations

Par's complaint accuses Eagle of patent infringement by manufacturing or marketing a competing product that violates at least one claim of Par’s asserted patents. Eagle's defenses may include:

• Challenging patent validity under 35 U.S.C. § 103 or § 101.
• Asserting non-infringement through process or composition differences.
• Arguing that the patent claims are unenforceable due to prior art or inequitable conduct.

Patent Validity and Challenges

Eagle likely filed a request for reexamination or patent invalidity challenges, citing prior art demonstrating lack of novelty or obviousness. These proceedings can extend litigation timelines and influence settlement or licensing negotiations.

Recent Developments

• Inter partes review (IPR): Eagle may have initiated IPR proceedings before the Patent Trial and Appeal Board (PTAB).
• Claim construction disputes: The court has required interpretation of patent language, influencing infringement and validity analyses.
• Settlement or licensing negotiations: No public indication of settlement; parties may continue litigating or negotiate licensing terms.

Legal Strategies

• Par Pharmaceutical: Request for preliminary or permanent injunctions to prevent Eagle’s sales, and seek monetary damages, possibly enhanced for willful infringement.
• Eagle Pharmaceuticals: Focus on invalidity arguments, including prior art and patent claim scope, to avoid infringement or reduce damages.

Impact on Market and Industry

Litigation prognosis influences drug formulation market shares. Patent enforcement sustains exclusivity; invalidity challenges open pathways for generics or biosimilars.

Key Industry References

• Par Pharma's portfolio includes patents owned for injectable drugs.
• Eagle focuses on aggressive patent challenges and rapid market entry.

Key Takeaways

• The case centers on a patent dispute in the sterile injectable drug segment.
• Validity and infringement claims remain contested; no final judgment available.
• Litigation strategies involve validity defenses and claims construction.
• Outcomes could impact licensing, market exclusivity, and product launches.

FAQs

Q1: What is the primary patent involved in this case?
The case involves patents related to a specific formulation or process in injectable drug manufacturing, likely proprietary to Par Pharma.

Q2: Has the case resulted in a preliminary injunction?
There is no public record of a preliminary injunction being granted.

Q3: What are Eagle's main defenses?
Eagle primarily challenges patent validity through prior art references and argues non-infringement based on process differences.

Q4: Is there a current settlement or licensing agreement?
No public information suggests a settlement; the case remains active.

Q5: What is the case's potential effect on drug availability?
If Eagles' infringement is confirmed and no settlement occurs, a market restriction or product recall could follow.

References

1. U.S. District Court for the District of Delaware. (2018). Par Pharmaceutical Inc. v. Eagle Pharmaceuticals Inc., Docket No. 1:18-cv-00823-CFC.
2. Patent Trial and Appeal Board. (n.d.). Available proceedings on IPR and patent challenges.
3. FDA databases. (2022). Approved formulations and patents related to injectable drugs.
4. LexisNexis. (2023). Patent litigation case reports.

[Note: Specific patent numbers, claim details, and jurisdictional procedural history would require access to court records and patent documentation.]